Technical Analysis for HEMO - Hemogenyx Pharmaceuticals Plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | -1.43% | |
| Bollinger Band Squeeze | Range Contraction | -1.43% | |
| Gapped Up | Strength | -1.43% | |
| 20 DMA Resistance | Bearish | -2.70% | |
| Shooting Star Candlestick | Bearish | -2.70% | |
| Bollinger Band Squeeze | Range Contraction | -2.70% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | about 20 hours ago |
| Down 3% | about 20 hours ago |
| Down 2% | about 20 hours ago |
| Down 1% | about 20 hours ago |
| Up 5% | about 20 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of novel therapies and treatments for blood diseases. It is developing products for bone marrow/hematopoietic stem cell BM/HSC transplant market, including CDX bi-specific antibody and CAR-T therapy for eliminating relapsed and/or refractory acute myeloid leukaemia, acute lymphoblastic leukaemia, and myelodysplastic syndrome; and Human Postnatal Hemogenic Endothelial Cells, a cell therapy product for BM/HSC transplants. Hemogenyx Pharmaceuticals Plc was founded in 2013 and is headquartered in London, the United Kingdom.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pharmaceutical Medicine Pharmaceuticals Disease Branches Of Biology Medical Specialties Clinic Plants Diseases Plastic Therapy Blood Antibody Cell Therapy Therapies Acute Myeloid Leukemia Stem Cells Refractory Cell Therapy Product Hematopoietic Stem Cell Transplantation Leukemia Myelodysplastic Syndrome Stage Biotechnology
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pharmaceutical Medicine Pharmaceuticals Disease Branches Of Biology Medical Specialties Clinic Plants Diseases Plastic Therapy Blood Antibody Cell Therapy Therapies Acute Myeloid Leukemia Stem Cells Refractory Cell Therapy Product Hematopoietic Stem Cell Transplantation Leukemia Myelodysplastic Syndrome Stage Biotechnology
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.134 |
| 52 Week Low | 0.04 |
| Average Volume | 13,614,930 |
| 200-Day Moving Average | 2.13 |
| 50-Day Moving Average | 2.00 |
| 20-Day Moving Average | 1.63 |
| 10-Day Moving Average | 1.62 |
| Average True Range | 0.12 |
| RSI (14) | 34.21 |
| ADX | 24.16 |
| +DI | 16.23 |
| -DI | 24.33 |
| Chandelier Exit (Long, 3 ATRs) | 1.42 |
| Chandelier Exit (Short, 3 ATRs) | 1.90 |
| Upper Bollinger Bands | 1.73 |
| Lower Bollinger Band | 1.54 |
| Percent B (%b) | 0.25 |
| BandWidth | 11.53 |
| MACD Line | -0.09 |
| MACD Signal Line | -0.12 |
| MACD Histogram | 0.0284 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.76 | ||||
| Resistance 3 (R3) | 1.76 | 1.70 | 1.73 | ||
| Resistance 2 (R2) | 1.70 | 1.66 | 1.70 | 1.72 | |
| Resistance 1 (R1) | 1.64 | 1.63 | 1.62 | 1.64 | 1.71 |
| Pivot Point | 1.59 | 1.59 | 1.57 | 1.59 | 1.59 |
| Support 1 (S1) | 1.53 | 1.54 | 1.50 | 1.53 | 1.46 |
| Support 2 (S2) | 1.47 | 1.52 | 1.47 | 1.45 | |
| Support 3 (S3) | 1.41 | 1.47 | 1.44 | ||
| Support 4 (S4) | 1.41 |
